C o r e C The Administrative Core (Core C) provides leadership and administrative support for the planning, coordination, implementation and ongoing review of the individual research projects, cores and program of clinical trials to be conducted under the proposed Program Project. To foster the scientific and clinical objectives ofthe individual projeds and the Program Project as a whole, this core conducts periodic meetings with the participating principal investigators to develop strategic plans and consensual decisions regarding program development and organizes periodic reviews of research progress and productivity by external scientific advisory committees. This Core also provides direction and coordination for the activities of the transplant program's integrated data management. The core also maintains and facilitates communication between investigators in the individual projects and cores through weekly conferences and research-in-progress presentations. Lastly, this Core provides fiscal management services for the projects and cores of the Program Project, and provides critical analytic support for the preparation of research progress reports and interim analyses of clinical trials as required by the IRB, NMDP, NIH and, as applicable the FDA.
This Administrative Core provides scientific leadership and overall direction to the Program. This ensures appropriately frugal use of limited resources for maximal effect. This core also has and will continue to foster rapid translation of discoveries made in the Research Project into clinical trials and ultimate extension to the community.
|Dao, Tao; Korontsvit, Tatyana; Zakhaleva, Victoria et al. (2017) An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology 6:e1252895|
|Peled, Jonathan U; Devlin, Sean M; Staffas, Anna et al. (2017) Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol 35:1650-1659|
|Getta, Bartlomiej M; Roshal, Mikhail; Zheng, Junting et al. (2017) Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. Biol Blood Marrow Transplant 23:1879-1886|
|Barba, Pere; Ratan, Ravin; Cho, Christina et al. (2017) Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 23:67-74|
|Barba, Pere; Hilden, Patrick; Devlin, Sean M et al. (2017) Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease Biol Blood Marrow Transplant 23:452-458|
|Boudreau, Jeanette E; Giglio, Fabio; Gooley, Ted A et al. (2017) KIR3DL1/ HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol 35:2268-2278|
|Ghosh, Arnab; Smith, Melody; James, Scott E et al. (2017) Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med 23:242-249|
|Fischer, Julius C; Bscheider, Michael; Eisenkolb, Gabriel et al. (2017) RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. Sci Transl Med 9:|
|Goldberg, Jenna D; Zheng, Junting; Ratan, Ravin et al. (2017) Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leuk Lymphoma 58:1859-1871|
|Ito, Reiko; Hale, Laura P; Geyer, Susan M et al. (2017) Late Effects of Exposure to Ionizing Radiation and Age on Human Thymus Morphology and Function. Radiat Res 187:589-598|
Showing the most recent 10 out of 435 publications